Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis.
Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis.
复制标题
DOI：
10.1038/sj.bjc.6690628
复制
发表时间：
1999-08
影响因子：
8.8
通讯作者：
Caldas, C
中科院分区：
文献类型：
--
作者：
Pharoah, PDP;Day, NE;Caldas, C
许多研究已经调查了p53基因的改变与乳腺癌的临床结果之间的关联，并且大多数研究者报告了在p53体细胞突变的乳腺癌病例中总体和无病生存率较差（如相对危险度（RH）大于1所示）。然而，不同的研究产生了差异很大的相对湿度估计值，范围从无风险（相对湿度= 1）到相对危险度为23，并不是所有这些结果都具有统计学意义。因此，我们回顾了所有已发表的研究，研究了p53基因体细胞突变和乳腺癌预后之间的关联，并使用标准的荟萃分析技术，联合收割机这些研究的结果，以产生一个更精确的估计p53突变的预后意义。11项研究调查了总计2319例患者的总生存率。这些数据的RH估计值范围为1 - 23.4，合并RH估计值为2.0（置信区间1.7-2.5）。三项研究调查了p53在淋巴结阴性患者中的作用，其中RH的综合估计值为1.7（1.2-2.3）。三项淋巴结阳性乳腺癌研究的综合风险估计值为2.6（1.7-3.9）。根据这些结果，在大型乳腺癌临床试验中纳入p53突变筛查似乎是必要的。分析大量病例的分期和治疗方法，将明确p53突变状态在恶性肿瘤诊断中的价值，并可能选择治疗方法。© 1999癌症研究运动
Many studies have investigated the association between alterations in the p53 gene and clinical outcome of breast cancer, and most investigators have reported poorer overall and disease-free survival (as indicated by a relative hazard (RH) greater than one) in breast cancer cases with somatic mutations in p53. However, different studies have produced widely differing RH estimates, ranging from no risk (RH = 1) to a relative hazard of 23, and not all of these results have been statistically significant. We have therefore reviewed all the published studies that have investigated the association between somatic mutations in the p53 gene and breast cancer prognosis and used standard techniques of meta-analysis to combine the results of these studies to produce a more precise estimate of the prognostic significance of p53 mutations. Eleven studies investigated overall survival in a total of 2319 unselected cases. The RH estimates from these ranged from 1 to 23.4 with a combined RH estimate of 2.0 (confidence interval 1.7–2.5). Three studies investigated the role of p53 in node-negative patients and in these, the combined estimate of RH was 1.7 (1.2–2.3). For three studies of node-positive breast cancer the combined risk estimate was 2.6 (1.7–3.9). The inclusion of p53 mutation screening in large breast cancer clinical trials seems warranted in the light of these results. Analysis of large numbers of cases matched for stage and therapy will allow definitive clarification of the value of p53 mutational status in prognostication, and possibly choice of therapy. © 1999 Cancer Research Campaign
登录
查看更多内容
影响因子：
3.3
作者：
BARNES, DM;DUBLIN, EA;MILLIS, RR
通讯作者：
MILLIS, RR
影响因子：
82.9
作者：
BERGH, J;NORBERG, T;HOLMBERG, L
通讯作者：
HOLMBERG, L
影响因子：
45.3
作者：
JANSSON, T;INGANAS, M;BERGH, J
通讯作者：
BERGH, J
DOI：
10.1093/jnci/85.3.200
发表时间：
1993-02-03
期刊：
JOURNAL OF THE NATIONAL CANCER INSTITUTE
影响因子：
--
作者：
ALLRED, DC;CLARK, GM;MCGUIRE, WL
通讯作者：
MCGUIRE, WL
DOI：
10.1073/pnas.93.3.1093
发表时间：
1996-02-06
影响因子：
11.1
作者：
Kovach, JS;Hartmann, A;Sommer, SS
通讯作者：
Sommer, SS